Roche is shutting down its research and development efforts in semiconductor sequencing and nanopore sequencing and is consolidating its 454 and NimbleGen products into a new sequencing unit that will cover both life science and clinical diagnostic applications.

The changes are part of the company's decision, announced today, to dissolve Roche Applied Science, the life science unit of its Diagnostics division, by the end of this year and to integrate Applied Science's products with other units.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."